FDA Confirms SeaStar Medical Fulfilled QUELIMMUNE Post-Approval Study Requirements
SeaStar Medical said the FDA confirmed it fulfilled post-approval study requirements for QUELIMMUNE in pediatric patients with sepsis-associated acute kidney injury.
Story updates
01:27:44 PM UTC
SquawkNews
FDA determined SeaStar Medical’s QUELIMMUNE pediatric SAVE Registry fulfilled its post-approval study requirements. Hospitals may now use the therapy without the registry’s research infrastructure; registry enrollment will continue voluntarily.Material DetailsContext by AI AnalystThis is a commerci…
01:34:17 PM UTC
SquawkNews
SeaStar Medical said the FDA confirmed QUELIMMUNE’s pediatric SAVE Registry fulfilled the therapy’s post-approval study requirements, enabling broader hospital access.Key Highlights:Original SEC Filing: SeaStar Medical Holding Corp [ ICU ] - 8-K - Nov. 03, 2026This is an AI-powered summary. It may…